TECH FLOW Svět Androida
← Back to the stream
research.uhs.nhs.uk · picked by Petr Mišák · 42d ago

CenSegNet reveals hidden centrosome patterns in breast cancer with new diagnostic insights

Source preview: CenSegNet reveals hidden centrosome patterns in breast cancer with new diagnostic insights
AI summary

Researchers at the University of Southampton developed CenSegNet, an open-source AI tool that analyzes centrosomes in tumour samples. Using this tool, they analyzed over 330,000 centrosomes from 911 breast cancer specimens and discovered two distinct types of centrosome abnormalities with different clinical implications—elevated centrosome numbers and abnormally enlarged centrosomes behave independently and affect tumour behaviour differently.

The summary is written by AI from the source; it isn’t the newsroom’s opinion. For details, read the source.

3 people have already opened the source

Tip author’s note

We live in a truly beautiful yet dangerous time. What was impossible yesterday is possible today. Cancer in general is a serious matter, but thanks to AI we could fight it better and perhaps in the future it will become something like today's flu. And AI hasn't even started using quantum computers yet—when it does, that will be a huge leap forward.

AI questions & answers
What are centrosomes and why are they important in cancer research?

Centrosomes are cellular organelles that function as the cell's organizing hubs, helping cells divide correctly and maintain structure. Their abnormalities have long been recognized as a hallmark of cancer because defective centrosomes lead to accumulation of genetic errors in cells.

How do the two types of centrosome abnormalities discovered in the study differ?

One type involves cells acquiring too many centrosomes, while the other involves abnormally enlarged centrosomes. The research showed that these defects behave independently and can occupy different regions within the same tumour.

What are the potential clinical applications of CenSegNet technology?

Applications include identifying patients with aggressive tumours, enabling precision oncology by matching patients to targeted treatments, and predicting tumour progression and treatment resistance. However, the technology is not yet ready for routine clinical use.

Questions and answers are written by AI about the topic, not taken from the source; they aren’t the newsroom’s opinion.
Related from the stream
Mentions
  • CenSegNet
  • University of Southampton
  • University Hospital Southampton
  • Dr Salah Elias
  • Nature Communications